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Study GroupAbstract
Objectives: The study aimed at prospectively evaluating the evolution of asthma control in Italy, to evaluate the
reasons for lack of asthma control, perceived quality of life (QoL) and association with level of asthma control, the
impact of pharmacological treatment, the number of exacerbations and the healthcare resource consumption.
Methods: PRISMA (PRospectIve Study on asthMA control) was an observational study performed in asthmatic
patients including a cross-sectional phase and a 12-month prospective phase. Asthma control was assessed with
the Asthma Control Test™ (ACT) and QoL was evaluated with EuroQoL-5D questionnaire filled in and collected
during 5 clinic visits together with all the other data.
Results: The prospective phase included 1017 patients with uncontrolled (55.7%) or partly controlled asthma
(44.3%). Out of the 739 patients evaluable after 12 months, 22.2% achieved full asthma control (ACT score = 25) and
58.7% reached a good control (ACT score: 20–24). The improvement in asthma control was associated with
improved QoL and reduced hospital visits. The main reasons for lack of asthma control were comorbidities,
continued exposure to irritants/triggers and poor adherence to therapy. The frequency of exacerbations was lower
in patients with controlled asthma.
A fixed combination therapy with an inhaled corticosteroid and a long-acting β2 agonist was reported by 77.0% of
patients. A better asthma control and improved QoL were achieved with extrafine beclomethasone/formoterol
compared to either budesonide/formoterol or fluticasone/salmeterol.
Conclusions: An improvement in asthma control and QoL can be achieved during a 1-year monitoring in a real life
setting. Extrafine beclomethasone/formoterol was associated with significant benefit in terms of asthma control and
QoL compared to large-particles combinations.
ClinicalTrials.gov number NCT01110460.Introduction
According to international guidelines, once treatment
has been established, therapeutic management of asthma
should be based on asthma control, rather than asthma
severity [1,2]. Patients with controlled asthma can pre-
vent the majority of attacks, avoid daytime and nighttime
symptoms, stay physically active and have reduced risk to
exacerbate [3].
Recognizing the importance of the patient’s perspec-
tive and of the poor correlation between lung function* Correspondence: g.nicolini@chiesi.com
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reproduction in any medium, provided the orand symptoms [3,4], clinical trials and clinical practice
have increasingly focused on the assessment of asthma
control. This is a general term that implies a global as-
sessment of actual status and future risk including symp-
toms, reliever use, lung function, and the frequency/
severity of exacerbations [5]. The level of asthma control
is usually categorized into controlled, partly controlled
and uncontrolled [1]. Moreover, a positive correlation be-
tween asthma control and quality of life (QoL) has been
demonstrated [3]. Awareness of patient reported outcomes
such as asthma control and QoL is increasing, together
with an emphasis in clinical research and by regulatory
bodies because of their relevance in the overall treatment
efficacy assessment [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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observational study was designed to include a cross-
sectional phase and a 12-month prospective phase in
order to estimate the level of asthma control in real life
and its evolution during a 1-year follow up. The results
of the cross-sectional phase of the PRISMA study, inves-
tigating the level of asthma control in 2853 patients
with asthma recruited in 56 respiratory clinics in Italy
have been recently published [6]. The main findings
indicate that despite a high proportion of patients have
controlled asthma, one third of patients are still un-
controlled or partly controlled. Previous studies were
available evaluating the control of asthma but com-
prised smaller populations and with a less representa-
tive distribution throughout the country [7-11]. In the
PRISMA study, patients filled in validated question-
naires for asthma control and QoL measurement and
data were collected during visits by respiratory specia-
lists. In contrast, previous studies have collected data
by telephone interviews [7-9], web-based question-
naires [11-13], or postal screening questionnaires [14].
Moreover, all the above studies are cross-sectional but
only prospective monitoring of patients’ asthma control
using composite measures can describe how this reflect
asthma outcomes and/or future risks [5]. Unfortunately,
no information is yet available on the rate of achieve-
ment of asthma control among poorly controlled asthma
patients. It has been suggested that monitoring outcomes
and taking appropriate action through regular visits may
improve current levels of asthma control [15]. Behavioral
factors such as smoking and non-adherence may reduce
the efficacy of treatment and patients' perceptions influ-
ence these behaviors. Under-treatment may also be related
to patients' underestimation of the significance of symp-
toms, and lack of awareness of achievable control. There
is a need to raise patient expectations by increasing aware-
ness of the QoL that could be attained.
The aim of the present study was to measure asthma
control in a prospective 12 months observation period
in patients whose asthma was classified as uncontrolled
or partly controlled in a cross-sectional phase visit [6].
The prospective phase described in this manuscript
aimed to evaluate the proportion of patients with uncon-
trolled or partly controlled asthma who achieve asthma
control at 12 months. Secondary objectives were: to
evaluate the reasons for lack of asthma control, per-
ceived QoL and association with level of asthma control,
the impact of pharmacological treatment, the number of
exacerbations and the healthcare resource consumption.
Methods
Study design
The PRISMA study was designed to include a cross-
sectional phase [6] and a 12-month prospective phase inorder to estimate the level of asthma control in real life
and its evolution during a 1-year follow up. Clinic visits
were performed every 3 months for a total of 5 visits
throughout the 1-year study period and data were col-
lected at each visit. The results of the cross-sectional
phase of the PRISMA study were previously published
[6]. Patients with uncontrolled or partly controlled
asthma in the cross-sectional phase were included in
the longitudinal phase of the study described hereafter.
According to the observational study design, no ran-
domisation procedure was implemented during the en-
rolment. The assignment of the patient to a particular
therapeutic strategy was not defined in the study proto-
col but fell within current practice according to the
physician’s decision.
The protocol was approved by the Institutional Review
Board of each centre, and informed written consent was
obtained from each participant prior to study initiation.
Patients
The first fifty consecutive patients visiting 56 Italian
pneumology centers were included in the cross-sectional
phase of the PRISMA study if they satisfied the following
criteria: i) provided written informed consent; ii) adult
patients, smokers and non-smokers, with a previous
asthma diagnosis of at least six months; iii) patients able
to understand and fill in the questionnaires. Exclusion
criteria were: i) patients included in clinical trials or who
have been attending one in the last 12 weeks; ii) patients
with severe and disabling diseases; iii) pregnant women.
Only patients who had uncontrolled or partly con-
trolled asthma according to the ACT score in the cross-
sectional visit were included in the prospective phase
here described.
Patient reported outcomes
The self-evaluating Asthma Control Test™ (ACT) was
used to determine the patients' level of disease control
in the 4 weeks preceding each clinic visit [4,16]. The
overall ACT score varies from 5 (very poor asthma con-
trol) to 25 (full asthma control) with scores ranging from
20 to 24 defining controlled asthma, scores ranging from
16 to 19 partly controlled asthma and scores ≤15 uncon-
trolled asthma [2,4]. The ACT has been validated pro-
spectively in several studies [5,17]. The EuroQoL-5D
questionnaire [18] (EQ-5D) was used to determine the
QoL perceived by the patient. It is a standardized self-
rating test which refers to the day of rating applicable to a
wide range of health conditions and treatments. EQ-5D
provides a score where the maximum value of 1 denotes
the best health status and 0 identifies a health status com-
parable to death. In addition, patients scaled their health
on a visual analogue scale (VAS) ranging from 0 to 100,
with 0 as the worst possible health status and 100 as the
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pleted by each participant at each visit.
Other variables
Current antiasthmatic therapies were recorded at each
visit (in terms of active ingredient, dosage, duration and
administration method). Patients were defined as treated
with a specific drug if they had evidence of treatment for
at least 5 consecutive days in the 3 months before the
visit. For the comparison of asthma control level among
treatments, only patients who had been on that therapy
in the last 4 weeks were included in the analysis to
match with ACT that evaluates asthma control in the
last 4 weeks [6]. Possible reasons for poor control were
described according to doctors’ opinion.
Exacerbations were registered along with the con-
sumption of healthcare resources due to asthma (hospi-
talizations, emergency room visits, outpatients visits) at
each clinic visit.
Exacerbations were defined as worsening of symptoms
requiring any of the following: an increase in therapy or
systemic corticosteroids, unscheduled specialist visit or
an access to an emergency room.
Statistical analysis
Due to the lack of prospective data on asthma control in
observational studies, the sample size was estimated on
the basis of the AIRE cross-sectional study [8]. The sam-
ple size was determined in order to have a relative error
lower than 30% based on available literature data. It was
estimated that a sample size of at least 1270 patients
with uncontrolled or partly controlled asthma in the
cross-sectional phase would have allowed to detect a
rate of 5.1% of patients reaching optimal asthma control
at the end of the 1-year prospective phase of the study,
with a 95% CI equal to 5.1 ± 1.40% (estimating a 25%
drop-out rate).
Summary statistics (mean, standard deviation) were
provided for continuous variables, and absolute and rela-
tive frequency distribution was provided for categorical
data. Comparisons between categorical variables were
analyzed by the Chi-square test (or Fisher exact test,
when appropriate). Comparisons between continuous
variables were performed by the Kruskal-Wallis test.
Post-hoc comparisons were performed, when applicable:
in such cases, Bonferroni's correction was applied.
Multivariate linear regression analyses were used in
order to assess the association between the QoL (EQ-5D
and VAS scores) and asthma control at the 12-month
follow-up visit. Age, gender, educational level, BMI,
smoking habits, asthma risk factors/triggers in the occu-
pational environment, concomitant disease, QoL and
asthma control (in the cross-sectional visit) were included
as covariates. Since the independent variables havedifferent scales, covariates were standardized. Significance
was set at a two-tailed p-value of 0.05. All statistical ana-
lyses were performed by using the statistical analysis soft-
ware "SAS version 9.2".
Results
Study population
Clinical characteristics of patients with uncontrolled or
partly controlled asthma in the cross-sectional phase are
summarized in Table 1 and patient flow during the 12-
month observation period is described in Figure 1. A
total of 1017 uncontrolled or partly controlled patients
were enrolled from January to October 2009 and fol-
lowed up for 12 months with approximately 70% attend-
ing follow-up visits (Figure 1). The mean age was
46 years and 66.3% (n = 674) were females. Patients with
uncontrolled asthma were 566 (55.7%), those with partly
controlled asthma were 451 (44.3%). Comparing patient
clinical characteristics between the uncontrolled and
partly controlled groups, a few significant differences
were observed: uncontrolled patients reported that they
had a poorer patient-doctor communication compared
to the partly controlled patients (25.3% vs. 16.2%, p <
0.001); the percentage of obese patients was higher
(22.3% vs. 16.6%, p = 0.021) and sinusitis was more fre-
quent among the uncontrolled patients (13.4% vs. 8.4%,
p = 0.012).
The most frequently reported therapies (at least 5 con-
secutive days of therapy in the last 3 months) were: a fixed
combination of an inhaled corticosteroid and a long acting
β2 agonist (ICS/LABA) in 48.3% of patients; leukotriene
receptor antagonists in 23.6% and ICS in 11.2%.
Clinical characteristics of patients (n = 739) attending
the 12-month follow-up visit are summarized in Table 2.
Asthma control
An improvement in asthma control was observed at the
first follow-up visit after 3 months, where 6.9% of patients
achieved full asthma control (Figure 2). Furthermore, the
proportion of patients achieving full asthma control
increased over time, reaching 22.2% on the last visit, with
58.7% of patients having controlled asthma, 11.8% partly
controlled asthma and 7.3% were still uncontrolled.
The main reasons for lack of asthma control as
declared by treating physicians were comorbidities in
36.2% of patients, continued exposure to irritants/trig-
gers in 34.0%, and poor adherence to therapy in 27.0%
(Table 3).
When comparing reasons for poor control after 1-year
follow-up with those reported in the cross-sectional visit,
poor adherence to therapy, lack of patient follow-up, poor
patient-doctor communication and inadequate therapy
were less frequently reported, whereas comorbidities were
reported more frequently (Table 3).
Table 1 Patients characteristics at the cross-sectional phase visit
Total Partly controlled Uncontrolled
Number of patients, n (%) 1017 (100) 451 (44.3) 566 (55.7)
Age, years, mean (SD) 46 (15) 45 (15) 47 (15)
Gender, n (%)
Males 343 (33.7) 160 (35.5) 183 (32.3)
Females 674 (66.3) 291 (64.5) 383 (67.7)
Duration of asthma, years, mean (SD) 17.4 (13.0) 16.4 (12.7) 18.2 (13.2)
Body mass index categories, n (%)
Obese (≥ 30 kg/m2) (1) 201 (19.8) 75 (16.6) 126 (22.3)
Overweight (≥ 25 and < 30 kg/m2) 357 (35.1) 162 (35.9) 195 (34.5)
Normal weight (≥ 18.5 and < 25 kg/m2) 390 (38.4) 188 (41.7) 202 (35.7)
Underweight (< 18.5 kg/m2) 32 (3.2) 12 (2.7) 20 (3.5)
Not available 37 (3.6) 14 (3.1) 23 (4.1)
Smoking habits, n (%)
Current smokers 197 (19.4) 77 (17.1) 120 (21.2)
Non-smokers 637 (62.6) 287 (63.6) 350 (61.8)
Ex-smokers (2) 174 (17. 1) 86 (19.1) 88 (15.6)
Not available 9 (0.9) 1 (0.2) 8 (1.4)
Concomitant diseases (3), n (%)
Total 640 (62.9) 287 (63.6) 353 (62.4)
Rhinitis 362 (35.6) 164 (36.4) 198 (35.0)
Cardiovascular diseases 151 (14.8) 70 (15.5) 81 (14.3)
Gastro-oesophageal reflux 171 (16.8) 68 (15.1) 103 (18.2)
Sinusitis (4) 114 (11.2) 38 (8.4) 76 (13.4)
Nasal polyposis 52 (5.1) 25 (5.5) 27 (4.8)
Type 2 diabetes 39 (3.8) 14 (3.1) 25 (4.4)
Respiratory infections 43 (4.2) 15 (3.3) 28 (5.0)
Psychological disturbances 25 (2.5) 9 (2.0) 16 (2.8)
Type 1 diabetes 5 (0.5) 2 (0.4) 3 (0.5)
Other diseases 108 (10.6) 42 (9.3) 66 (11.7)
Quality of life, n 1010 448 562
EQ-5D (5) score, mean (SD) 0.72 (0.2) 0.75 (0.2) 0.69 (0.2)
EQ-5D (5) VAS score, mean (SD) 65.1 (15.6) 68.6 (14.9) 61.5 (16.3)
(1) Overall p = 0.021; (2) Patients who stopped smoking since at least one year; (3) Patients could have more than one concomitant disease; (4) Overall p = 0.012;
(5) EQ-5D: EuroQoL-5D questionnaire.
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in the last 4 weeks before the end of the study (n = 569),
19.0% had fully controlled asthma, 61.7% had controlled
asthma, 12.0% had partly controlled asthma and 7.4%
had uncontrolled asthma.
Three hundred and one patients were in treatment
with the extrafine beclomethasone/formoterol (BDP/F)
combination in a pressurized Metered Dose Inhaler
(pMDI), 145 were in treatment with budesonide/formo-
terol (BUD/F) Dry Powder Inhaler (DPI) and 123 with flu-
ticasone/salmeterol (FP/S; 46.3% pMDI and 53.7% DPI).
When comparing the different available combinations, agreater proportion of patients treated with the extrafine
BDP/F combination achieved asthma control compared to
patients treated with either BUD/F or FP/S (Table 4,
Figure 3). The proportion of patients with full asthma
control in the extrafine BDP/F-treated group was signifi-
cantly greater than in the BUD/F-treated group (Bonferro-
ni’s corrected p < 0.001; Figure 3). Moreover, an
improvement of 3 points in the ACT score was achieved
by a significantly greater proportion of BDP/F treated
patients as compared to BUD/F treated patients
(Table 4). The probability of having full asthma control
was higher in patients treated with extrafine BDP/F than
Figure 1 Patient flow. Patients were considered as drop-out if they definitely withdrew from the study; patients were considered as lost to
follow-up if they missed one visit but they attended to a subsequent follow-up visit.
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CI: 1.733 to 8.374; Bonferroni’s corrected p < 0.001) and
FP/S (odds ratio 1.9; 95% adjusted CI: 0.957 to 3.699; Bon-
ferroni’s corrected p = 0.075).
The mean daily dose of ICS administered was approxi-
mately 2-fold lower for extrafine BDP/F compared to ei-
ther BUD/F or FP/S (Table 4).Quality of life and exacerbations
The EQ-5D and VAS scores at the 12-month follow-up
visit were higher in patients with controlled asthma as
compared to patients with partly controlled or uncon-
trolled asthma (Table 2). When covariates were taken
into account, control at the 12-month visit, age and QoL
in the cross-sectional visit were shown to be associated
with 12-month QoL (p < 0.001).Patients treated with extrafine BDP/F had a signifi-
cantly higher EQ-5D score compared to BUD/F (0.88
± 0.18 vs. 0.82 ± 0.19, Bonferroni’s corrected p = 0.001;
Figure 4). Furthermore, a significantly higher VAS
score was detected in the extrafine BDP/F-treated
group (82.7 ± 12.5) compared to either BUD/F (74.9 ±
14.1, Bonferroni’s corrected p < 0.0001) or FP/S-trea-
ted patients (77.0 ± 13.6, Bonferroni’s corrected p <
0.001; Figure 4).
A total of 589 exacerbations were reported during
the 1-year follow up. The percentage of patients
reporting exacerbations was lower, at all follow-up vis-
its, in patients with controlled asthma compared to
the sum of patients with partly controlled and uncon-
trolled asthma (p < 0.001). In the last 3 months before
the end of the study, at least one exacerbation was reported
by 67% of patients with partly controlled and uncontrolled
Table 2 Patient characteristics at the 12-month follow-up visit
Total Controlled Partly controlled Uncontrolled Overall p-value
Number of patients, n (%) 739 598 (80.9) 87 (11.8) 54 (7.3)
Smoking habits, n (%) (1) 0.437
Current smokers 136 (18.4) 113 (18.9) 14 (16.1) 9 (16.7)
Non-smokers 468 (63.3) 384 (64.2) 50 (57.5) 34 (63.0)
Ex-smokers (2) 128 (17.3) 97 (16.2) 21 (24.1) 10 (18.5)
Not available 7 (0.9) 4 (0.7) 2 (2.3) 1 (1.9)
Improvement of 3 points in ACT score, n (%) 642 (86.9) 572 (95.7) 55 (63.2) 15 (27.8) <0.001(3)
Quality of life, n 733 593 86 54
EQ-5D(4) score, mean (SD) 0.87 (0.19) 0.91 (0.13) 0.71 (0.23) 0.62 (0.30) <0.001(5)
EQ-5D(4) VAS score, mean (SD) 80.0 (13.6) 83.8 (10.2) 67.2 (12.1) 58.9 (16.0) <0.001(6)
Antiasthmatic therapy, n (%) (7)
No therapy 59 (8.0) 55 (9.2) 3 (3.5) 1 (1.9) -
ICS /LABA 602 (81.5) 484 (80.9) 72 (82.8) 46 (85.2) -
LTRA 237 (32.1) 165 (27.6) 42 (48.3) 30 (55.6) -
ICS 71 (9.6) 55 (9.2) 7 (8.1) 9 (16.7) -
Short-acting β2agonist 42 (5.7) 21 (3.5) 13 (14.9) 8 (14.8) -
(1) Smoking habits was reported only at the cross-sectional phase visit; (2) Patients who stopped smoking since at least one year; (3) Bonferroni’s corrected
p < 0.001 for all comparisons; (4) EQ-5D: EuroQoL-5D questionnaire; (5) Bonferroni’s corrected p < 0.001 patients with controlled asthma vs. patients with partly
controlled and uncontrolled asthma; Bonferroni’s corrected p = 0.060 patients with partly controlled asthma vs. patients with uncontrolled asthma; (6) Bonferroni’s
corrected p < 0.001 patients with controlled asthma vs. patients with partly controlled and uncontrolled asthma; Bonferroni’s corrected p = 0.004 patients with
partly controlled asthma vs. patients with uncontrolled asthma; (7) Data are percentage of patients in each category of asthma control reporting therapies for at
least 5 consecutive days in the last 3 months; patients could have more than one pharmacologic class therapy; ICS: inhaled corticosteroids; LABA: long-acting β2
agonist; LTRA: leukotriene receptor antagonists.
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(p < 0.001).
The percentage of patients reporting exacerbations in
the last 3 months before the 12-month visit was 13.3%
in patients treated with extrafine BDP/F, 13.1% inFigure 2 Evolution of asthma control during the 12-month
prospective phase. Data are presented as percentage of patients in
each category of asthma control: fully controlled (ACT score = 25),
controlled (ACT score: 24–20), partly controlled (ACT score: 19–16)
and uncontrolled (ACT score≤ 15).patients treated with BUD/F and 20.3% in patients trea-
ted with FP/S.Consumption of healthcare resources
A significant decrease in healthcare resource consump-
tion was detected during the 1-year follow-up (Figure 5).
The percentage of patients requiring an outpatient visit
in the last 3 months before the 12-month visit was
reduced approximately 3-fold to 24.5% (compared to 62%
at the beginning of the study, p < 0.001). The proportion
of patients that were admitted to hospital was also
reduced from 5.8% in the cross-sectional visit to 0.5% in
the 12-month follow-up visit (p < 0.001). The frequency
of emergency room visits was also significantly reduced,
from 15.4% in the cross-sectional visit to 1.9% in the last
follow-up visit (p < 0.001).Discussion
PRISMA is the first prospective observational study spe-
cifically designed to evaluate the proportion of patients
achieving asthma control during a 1-year follow-up in
real life conditions.
The main findings from this prospective study demon-
strate that 22.2% of patients that previously had partly
controlled or uncontrolled asthma (n = 739) achieved full
asthma control after 1 year, 58.7% had controlled asthma,
Table 3 Comparison between the reasons for lack of asthma control at the cross-sectional visit and at the 12-month
follow-up visit
Reasons for lack of asthma control,
n (%) (1)
Cross-sectional phase visit 12-month follow-up visit
Total n = 1017 Total n = 141 p-value (2)
Comorbidities 154 (15.1) 51 (36.2) <0.001
Continued exposure to irritants/triggers 295 (29.0) 48 (34.0) 0.238
Poor adherence to therapy 440 (43.3) 38 (27.0) <0.001
Smoking habits 154 (15.1) 11 (7.8) 0.020
Lack of patient follow up 405 (39.8) 9 (6.4) <0.001
Inadequate therapy 202 (19.9) 8 (5.7) <0.001
Poor patient-doctor communication 216 (21.2) 5 (3.6) <0.001
Inadequate inhalation technique 63 (6.2) 4 (2.8) 0.125
(1) According to the doctor’s opinion; Patients could have more than one reason; (2) Fisher exact test between the cross-sectional visit and the 12-month follow-up
visit.
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uncontrolled.
Among those patients who, after the 1-year follow-up,
did not attain asthma control (n = 141), the reasons were
anyway different, according to the physician assessment,
from those at study start. Actually, when comparing the
last visit of the prospective phase with the cross-sectional
visit, reasons for lack of asthma control changed from
lack of adequate therapy/follow-up/communication or
smoking habits, i.e. all external factors that therefore can
be improved by a better asthma care, to the presence of
comorbidities. This finding suggests that during 1-year
monitoring in real life conditions, an improvement inTable 4 Characteristics of patients treated with ICS/LABA fixe
follow-up visit
Total n = 569 BDP/F ex
Level of asthma control, n (%)
Fully controlled 108 (19.0) 7
Controlled 351 (61.7) 17
Partly controlled 68 (12.0) 3
Uncontrolled 42 (7.4) 2
Current smokers, n (%) 110 (19.3) 6
Fully controlled 25 (22.7) 2
Controlled 66 (60.0) 3
Partly controlled 12 (10.9) 7
Uncontrolled 7 (6.4)
ACT score, mean (SD) 21.5 (3.4) 2
Improvement of 3 points in ACT score, n (%) 493 (86.6) 26
Daily Dose of ICS, n 537
Mean mcg (SD) NA 318
Patients with exacerbation, n (%) (5) 84 (14.8) 4
BDP/F: beclomethasone/formoterol; BUD/F: budesonide/formoterol; FP/S: fluticasone
corrected p < 0.001 BDP/F vs. BUD/F; Bonferroni’s corrected p = 0.039 BDP/F vs. FP/S
p < 0.001 BDP/F vs. BUD/F and FP/S; Bonferroni’s corrected p < 0.001 BUD/F vs. FP/Spatient behavioral factors that contribute to the lack of
asthma control such as adherence to medication, patient-
doctor communication and follow up can be obtained.
An additional observation coming from the present study
is that the rate of outpatients visits, hospitalizations and
emergency room visits was reduced approximately 3-fold
by the end of the follow-up period. This is in line with
the AIRE study that examined the use of healthcare
resources in 7 European countries and showed that worse
asthma control was associated with an increased require-
ment for unscheduled care and higher costs [8].
Moreover, our findings indicate that asthma control
can be achieved in a great proportion of patients treatedd combinations for at least 4 weeks before the 12-month
trafine n = 301 BUD/F n = 145 FP/S n = 123 Overall p-value
0.001(1)
7 (25.6) 12 (8.3) 19 (15.4)
3 (57.5) 102 (70.3) 76 (61.8)
1 (10.3) 18 (12.4) 19 (15.4)
0 (6.6) 13 (9.0) 9 (7.3)
9 (22.9) 25 (17.2) 16 (13.0) 0.617
0 (29.0) 3 (12.0) 2 (12.5) 0.135
9 (56.5) 17 (68.0) 10 (62.5)
(10.1) 3 (12.0) 2 (12.5)
3 (4.4) 2 (8.0) 2 (12.5)
2.0 (3.4) 20.7 (3.6) 21.3 (3.3) <0.001(2)
8 (89.0) 116 (80.0) 109 (88.6) 0.024(3)
287 141 122
.8 (114.3) 651.1 (291.2) 750.6 (371.7) <0.001(4)
0 (13.3) 19 (13.1) 25 (20.3) 0.145
/salmeterol; (1) Bonferroni’s corrected p = 0.001 BDP/F vs. BUD/F; (2) Bonferroni’s
; (3) Bonferroni’s corrected p = 0.029 BDP/F vs. BUD/F; (4) Bonferroni’s corrected
; (5) Reported in the last 3 months before the 12-month visit.
Figure 3 Percentage of patients treated with different ICS/
LABA fixed combinations with fully controlled (ACT score = 25),
controlled (ACT score: 24–20), partly controlled (ACT score: 19–
16) and uncontrolled (ACT score ≤ 15) asthma at the 12-month
follow-up visit. BDP/F = beclomethasone/formoterol; BUD/F =
budesonide/formoterol; FP/S = fluticasone/salmeterol. *Bonferroni’s
corrected p < 0.001 BDP/F vs. BUD/F (for fully controlled patients).
Figure 5 Percentage change in healthcare resource
consumption due to asthma from 3 months before the cross-
sectional phase visit to 3 months before the 12-month follow-
up visit. *p < 0.001 for all comparisons.
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agreement with recent observational studies reporting the
ICS/LABA combination being the most effective treatment
choice [19-21]. In a 12-month office-based observational
study, patients recently started on FP/S combination, had
significantly greater improvement in both asthma control
and QoL, compared with patients newly started onFigure 4 Quality of life (EQ-5D score and VAS) in patients
treated with different ICS/LABA fixed combinations at the 12-
month follow-up visit. BDP/F = beclomethasone/formoterol; BUD/
F = budesonide/formoterol; FP/S = fluticasone/salmeterol. Data are
means. *Bonferroni’s corrected p = 0.001 BDP/F vs. BUD/F;
§Bonferroni’s corrected p < 0.001 BDP/F vs. BUD/F and FP/S.montelukast [20]. Another study with a 12-month real life
observation period showed a greater change in asthma
control score in FP/S treated patients compared to other
forms of treatment that were in accordance with asthma
treatment guidelines (including BUD/F but not including
BDP/F extrafine) [21]. We observed that a greater propor-
tion of patients treated with extrafine BDP/F fixed com-
bination achieved good asthma control and the maximum
ACT score (i.e. full control) compared to either BUD/F or
FP/S -treated patients, the difference being significant ver-
sus BUD/F. Moreover, the proportion of patients achieving
a clinically meaningful change in ACT score (3 points) was
greater in BDP/F treated patients compared to BUD/F
treated patients. We considered only patients who had
been on the same therapy in the last 4 weeks for the com-
parison of asthma control level among treatments to
match with ACT that evaluates asthma control in the last
4 weeks.
As regards QoL assessed by EQ-5D, an improvement
of approximately 21% was observed after 1 year in the
whole population studied. When looking at patients
treated with ICS/LABA fixed combinations, extrafine
BDP/F-treated patients experienced significantly higher
QoL compared to either BUD/F or FP/S-treated patients
at the end of the 12-month observation period. These
results are consistent with those obtained in the cross-
sectional phase of the PRISMA study [6] and may be
attributed to the formulation of this combination, which
is characterized by extrafine particles able to reach and
treat the whole bronchial tree, including small airways
[22]. Indeed, asthma control and QoL correlate with
functional parameters reflecting small airways function
and improvements in ventilation heterogeneity are asso-
ciated with improvements in symptoms [23,24].
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http://respiratory-research.com/content/13/1/112A better asthma control with extrafine BDP/F combin-
ation compared to BUD/F and FP/S combinations was
recently shown in two observational cross-sectional
studies [6,25]. This is also confirmed by results from a
recent observational study which showed that initiating
or increasing therapy with an extrafine beclomethasone
formulation results in similar or better asthma control
compared with non-extrafine fluticasone [26].
The evidence of improvement in asthma control and
QoL in patients treated with extrafine formulations com-
pared to large particles formulations is supported by
randomized controlled trials (RCTs) [27,28]. Moreover,
an RCT demonstrated that a greater asthma control was
achieved in patients treated with extrafine BDP/F com-
bination compared to the same drugs administered with
separate inhalers delivering large particles [29]. This
evidence is particularly interesting when compared with
similarly designed studies with the other two available
combinations, as shown in a recently published review,
thus supporting the concept of greater efficacy of BDP/F
due to extrafine particles [30].
The difference in asthma control was detected despite
the lower ICS dose and the higher percentage of smo-
kers in the BDP/F patient cohort. This is of particular
interest since smoking is associated with an increased
risk of poor control [31,32] and asthmatic smokers are
less responsive to ICS therapy [33,34]. Our findings sup-
port the concept that the tobacco smoke-drug particle
interactions, which contribute to drug resistance, are less
likely to occur in case of extra-fine formulations [35].
Together, these results suggest that asthmatic smokers
can particularly benefit from extrafine BDP/F combin-
ation. This is also supported by a recently published pro-
spective real-life study showing significant improvements
in pulmonary function and asthma control in patients
treated with extrafine BDP/F combination with the same
treatment benefits observed in former or current smokers
compared with non-smoking asthmatics [36].
Someone may argue that the level of asthma control
detected in the present study is quite high compared to the
GOAL study in which patients were stepped up for a
1-year period to the highest recommended dose of FP/S
combination [37]. However, this difference can be
explained by the different patient population, definition of
control and way of measuring it. In the GOAL study only
patients with uncontrolled asthma were recruited and the
definition of control as from asthma international guide-
lines included lung function. Moreover, the definition of
“total control” used in the GOAL study was very stringent
(defined by achievement of all specified criteria for 7 weeks
in each 8-week period) and now abandoned [1,2]. By con-
trast, the ACT used in the present study is a validated pa-
tient reported outcome [4,5,16,17] and does not include
lung function which has been shown having minimalimpact on the reliability, responsiveness, and both cross-
sectional and prospective validity of the instrument [38].
Observational studies present some limitations such as
the possibility of unmeasured or unrecognized confounding
factors or influences on prescribing. These results should
be interpreted in light of the inherent limitations of non-
randomized, uncontrolled studies. However, these limits
are balanced by the broader applicability of observational
real life data on larger and more representative patient
populations with common co-morbidities and that can
identify clinically important differences among treat-
ments [39]. By contrast, RCTs have limited external val-
idity as they have been performed on highly selected
patient populations and most of the participants cur-
rently under asthma treatment in the community are not
represented [40].
In conclusion, the main findings from this prospective
phase of the PRISMA study demonstrate that an improve-
ment in asthma control can be achieved during a 1-year
monitoring in a real life setting. Furthermore, patients
have improved QoL and reduced hospital visits. Fixed
combination of extrafine BDP/F was associated with sig-
nificant benefit in terms of asthma control and QoL com-
pared to large-particles combinations, this advantage
likely being attributed to the extrafine formulation.
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